Novo Nordisk in Danish police probe for Tresiba disclosure delay
This article was originally published in Scrip
Novo Nordisk has been reported to the police by the Danish Financial Supervisory Authority for failing to disclose inside information as soon as possible. The reporting relates to the company's receipt of the complete response letter (CRL) from the US FDA for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart) on the evening of Friday 8 February 2013. Novo published the FDA's decision in a company announcement on Sunday 10 February (scripintelligence.com, 11 February 2013). However, the Danish Financial Supervisory Authority is of the opinion that Novo should have issued an announcement on the Friday evening.